Literature DB >> 19165087

Should biomarker estimates of HIV incidence be adjusted?

Ron Brookmeyer1.   

Abstract

OBJECTIVE: To evaluate adjustment procedures that have been proposed to correct HIV incidence rates derived from cross-sectional surveys of biomarkers (e.g. BED capture enzyme immunoassay). These procedures were motivated by some reports that the biomarker BED approach overestimates incidence when compared to cohort studies.
DESIGN: Consideration of the Hargrove and McDougal adjustment procedures that adjust biomarker estimates of HIV incidence rates for misclassification with respect to the timing of infections.
METHODS: : Performed mathematical and statistical analysis of the adjustment formulas. Evaluated sources of error in cohort studies of incidence that could also explain discrepancies between cohort and biomarker estimates.
RESULTS: The McDougal adjustment has no net effect on the estimate of HIV incidence because false positives exactly counterbalance false negatives. The Hargrove adjustment has a mathematical error that can cause significant underestimation of HIV incidence rates, especially if there is a large pool of prevalent long-standing infections.
CONCLUSION: The two adjustment procedures of biomarker incidence estimates evaluated here that purport to correct for misclassification do not increase accuracy and in some situations can introduce significant bias. Instead, the accuracy of biomarker estimates can be increased through improvements in the estimates of the mean window period of the populations under study and the representativeness of the cross-sectional samples. Cohort estimates of incidence are also subject to important sources of error and should not blindly be considered the gold standard for assessing the validity of biomarker estimates.

Mesh:

Substances:

Year:  2009        PMID: 19165087     DOI: 10.1097/QAD.0b013e3283269e28

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  25 in total

1.  Can HIV incidence testing be used for evaluating HIV intervention programs? A reanalysis of the Orange Farm male circumcision trial (ANRS-1265).

Authors:  Agnès Fiamma; Pascale Lissouba; Oliver E Amy; Beverley Singh; Oliver Laeyendecker; Thomas C Quinn; Dirk Taljaard; Bertran Auvert
Journal:  BMC Infect Dis       Date:  2010-05-27       Impact factor: 3.090

2.  Reply to 'Should biomarker estimates of HIV incidence be adjusted?'.

Authors:  Alex Welte; Thomas A McWalter; Till Bärnighausen
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

3.  A new general biomarker-based incidence estimator.

Authors:  Reshma Kassanjee; Thomas A McWalter; Till Bärnighausen; Alex Welte
Journal:  Epidemiology       Date:  2012-09       Impact factor: 4.822

4.  Interpopulation variation in HIV testing promptness may introduce bias in HIV incidence estimates using the serologic testing algorithm for recent HIV seroconversion.

Authors:  Edward White; Gary Goldbaum; Steven Goodreau; Thomas Lumley; Stephen E Hawes
Journal:  Sex Transm Infect       Date:  2010-06-24       Impact factor: 3.519

5.  Using tests for recent infection to estimate incidence: problems and prospects for HIV.

Authors:  A Welte; T A McWalter; O Laeyendecker; T B Hallett
Journal:  Euro Surveill       Date:  2010-06-17

6.  Augmented cross-sectional studies with abbreviated follow-up for estimating HIV incidence.

Authors:  B Claggett; S W Lagakos; R Wang
Journal:  Biometrics       Date:  2011-06-13       Impact factor: 2.571

7.  Estimation of HIV-1 incidence among five focal populations in Dehong, Yunnan: a hard hit area along a major drug trafficking route.

Authors:  Song Duan; Sheng Shen; Marc Bulterys; Yujiang Jia; Yuecheng Yang; Lifeng Xiang; Fei Tian; Lin Lu; Yao Xiao; Minjie Wang; Manhong Jia; Huazhou Jiang; Sten H Vermund; Yan Jiang
Journal:  BMC Public Health       Date:  2010-04-07       Impact factor: 3.295

8.  Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil.

Authors:  Carlos A Velasco de Castro; Beatriz Grinsztejn; Valdiléa G Veloso; Francisco I Bastos; José H Pilotto; Mariza G Morgado
Journal:  BMC Infect Dis       Date:  2010-07-28       Impact factor: 3.090

9.  On the use of adjusted cross-sectional estimators of HIV incidence.

Authors:  Rui Wang; Stephen W Lagakos
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

10.  A comparison of biomarker based incidence estimators.

Authors:  Thomas A McWalter; Alex Welte
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.